Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 3/2011

01-03-2011 | Systematic Review

Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies

Published in: Intensive Care Medicine | Issue 3/2011

Login to get access

Abstract

Purpose

Low-dose steroids have shown contradictory results in trials and three recent meta-analyses. We aimed to assess the efficacy and safety of low-dose steroids for severe sepsis and septic shock by Bayesian methodology.

Methods

Randomized trials from three published meta-analyses were reviewed and entered in both classic and Bayesian databases to estimate relative risk reduction (RRR) for 28-day mortality, and relative risk increase (RRI) for shock reversal and side effects.

Results

In septic shock trials only (Marik meta-analysis; N = 965), the probability that low-dose steroids decrease mortality by more than 15% (i.e., RRR > 15%) was 0.41 (0.24 for RRR > 20% and 0.14 for RRR > 25%). For severe sepsis and septic shock trials combined, the results were as follows: (1) for the Annane meta-analysis (N = 1,228), the probabilities were 0.57 (RRR > 15%), 0.32 (RRR > 20%), and 0.13 (RRR > 25%); (2) for the Minneci meta-analysis (N = 1,171), the probability was 0.57 to achieve mortality RRR > 15%, 0.32 (RRR > 20%), and 0.14 (RRR > 25%). The removal of the Sprung trial from each analysis did not change the overall results. The probability of achieving shock reversal ranged from 65 to 92%. The probability of developing steroid-induced side effects was as follows: for gastrointestinal bleeding (N = 924), there was a 0.73 probability of steroids causing an RRI > 1%, 0.70 for RRI > 2%, and 0.67 for RRI > 5%; for superinfections (N = 964), probabilities were 0.81 (RRI > 1%), 0.76 (RRI > 2%), and 0.70 (RRI > 5%); and for hyperglycemia (N = 540), 0.99 (RRI > 1%), 0.97 (RRI > 2%), and 0.94 (RRI > 5%).

Conclusions

Based on clinically meaningful thresholds (RRR > 15–25%) for mortality reduction in severe sepsis or septic shock, the Bayesian approach to all three meta-analyses consistently showed that low-dose steroids were not associated with survival benefits. The probabilities of developing steroid-induced side effects (superinfections, bleeding, and hyperglycemia) were high for all analyses.
Appendix
Available only for authorised users
Literature
1.
2.
Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M (1984) The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311:1137–1143CrossRefPubMed
3.
The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665CrossRef
4.
Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439CrossRefPubMed
5.
Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650CrossRefPubMed
6.
Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732CrossRefPubMed
7.
Chawla K, Kupfer Y, Goldman I, Tessler S (1999) Hydrocortisone reverses refractory septic shock. Crit Care Med 27(1):A33CrossRef
8.
Yildiz O, Doganay M, Aygen B, Guven M, Kelestimur F, Tutuu A (2002) Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 6:251–259CrossRefPubMed
9.
Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457–2464CrossRefPubMed
10.
Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871CrossRefPubMed
11.
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS Study Group (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124CrossRefPubMed
12.
Minneci PC, Deans KJ, Eichacker PQ, Natanson C (2009) The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 15:308–318CrossRefPubMed
13.
Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301:2362–2375CrossRefPubMed
14.
Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M, American College of Critical Care Medicine (2008) Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36:1937–1949CrossRefPubMed
15.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMed
16.
Annane D, Trabold F, Sharshar T, Jarrin I, Blanc AS, Raphael JC, Gajdos P (1999) Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 160:458–465PubMed
17.
Center for Drug Evaluation and Research (CDER) (2005) Reviewer guidance on conducting a clinical safety review of a new product application and preparing a report on the review. US FDA, Rockville, MD
18.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
19.
20.
Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR (2000) Bayesian methods in health technology assessment: a review. Health Technol Assess 4:1–130PubMed
21.
Kalil AC, Sun J (2008) Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis. PLoS One 3:e2291CrossRefPubMed
22.
Kalil AC, Sun J (2008) How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. Intensive Care Med 34:1804–1811CrossRefPubMed
23.
Spiegelhatler DJ, Abrams KR, Myles JP (eds) (2004) Bayesian approaches to clinical trials and health-care evaluation. Wiley,West Sussex, p 170
24.
Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R (2007) Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 131:954–963CrossRefPubMed
25.
Mussack T, Briegel J, Schelling G, Biberthaler P, Jochum M (2005) Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med 43:259–268CrossRefPubMed
26.
Luboshitzky R, Qupti G (2008) Corticosteroids for septic shock. N Engl J Med 358:2069, author reply 2070–2071PubMed
27.
Dellinger RP (2008) Steroid therapy of septic shock: the decision is in the eye of the beholder. Crit Care Med 36:1987–1989CrossRefPubMed
28.
Moraes RB, Czepielewski MA, Friedman G (2009) Is the cortrosyn test necessary in high basal corticoid patients with septic shock? Crit Care Med 37:385–386, author reply 386–387CrossRefPubMed
29.
Salluh JI, Soares M (2008) New recommendations for the use of corticosteroids in sepsis: not so fast! Crit Care Med 36:2489–2490, author reply 2490CrossRefPubMed
30.
Lamontagne F, Meade MO (2008) Low-dose hydrocortisone did not improve survival in patients with septic shock but reversed shock earlier. ACP J Club 148:6PubMed
31.
Seam N (2008) Corticosteroids for septic shock. N Engl J Med 358:2068–2069, author reply 2070–2071CrossRefPubMed
32.
33.
Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C (2002) Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197–1205CrossRefPubMed
34.
Li Y, Cui X, Li X, Solomon SB, Danner RL, Banks SM, Fitz Y, Annane D, Natanson C, Eichacker PQ (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 34:568–577CrossRefPubMed
35.
Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM, Edusepsis Study Group (2009) Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180:861–866CrossRefPubMed
36.
Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222–231CrossRefPubMed
37.
Bagshaw SM, Egi M, George C, Bellomo R, for the ANZICS Database Management Committee (2009) Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 37:463–470CrossRefPubMed
38.
Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557–1558CrossRefPubMed
39.
Lorente JA, Landin L, De Pablo R, Renes E, Liste D (1993) l-arginine pathway in the sepsis syndrome. Crit Care Med 21:1287–1295CrossRefPubMed
40.
Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34–39CrossRefPubMed
41.
Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J, Glaxo Wellcome International Septic Shock Study Group (2004) Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 32:1–12CrossRefPubMed
42.
López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21–30CrossRefPubMed
43.
Moraes RB, Czepielewski MA (2009) Corticosteroid therapy for severe sepsis and septic shock. JAMA 302:1643–1644, author reply 1644–1645CrossRefPubMed
44.
Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242–248CrossRefPubMed
45.
Tandan SM, Guleria R, Gupta N (2005) Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Am J Respir Crit Care Med 171:A24
46.
Rinaldi S, Adembri C, Grechi S, De Gaudio AR (2006) Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 34:2334–2339CrossRefPubMed
47.
Cicarelli DD, Bensenor FE, Vieira JE (2006) Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J 124:90–95CrossRefPubMed
Metadata
Title
Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies
Publication date
01-03-2011
Published in
Intensive Care Medicine / Issue 3/2011
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-010-2121-0

Other articles of this Issue 3/2011

Intensive Care Medicine 3/2011 Go to the issue

Original

Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy

Editorial

Improving the quality of training programs in intensive care: a view from the ESICM

Experimental

Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation

Original

The metrics of glycaemic control in critical care

Original

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease

Review

Interpretation of blood pressure signal: physiological bases, clinical relevance, and objectives during shock states